

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

21-015

APPROVAL LETTER

FEB 28 2000

NDA 21-015

Unimed Pharmaceuticals, Inc.
Attention: Judy Athey
Assistant Manager, Regulatory Affairs
2150 East Lake Cook Road
Buffalo Grove, IL 60089

APPEARS THIS WAY
ON ORIGINAL

Dear Ms. Athey:

Please refer to your new drug application (NDA) dated April 28, 1999, received April 29, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for AndroGel (testosterone gel).

We acknowledge receipt of your submissions dated June 17, August 9 and 18, September 16 and 21, October 6 and 25, November 19, December 9, 1999; January 21 and 24, February 9 (2), 11 (2), 14, 15, 17, 18, 23, 25 (2-facsimiles) and 28 (2-facsimiles), 2000.

This new drug application provides for the use of AndroGel (testosterone gel) for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted and patient package insert submitted February 28, 2000 (facsimile), immediate container and carton labels submitted January 21, 2000). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved NDA 21-015." Approval of this submission by FDA is not required before the labeling is used.

We remind you of your Phase 4 commitments specified in your submission dated February 25, 2000. These commitments, along with any completion dates agreed upon, are listed below.

Submit relevant evidence that there is no difference in clinical delivery of testosterone (as measured by testosterone levels) from the marketed AndroGel™ batches as compared to the clinical trial formulation.

Protocols, data, and final reports should be submitted to your IND for this product and a copy of the cover letter sent to this NDA. If an IND is not required to meet your Phase 4 commitments, please submit protocols, data and final reports to this NDA as correspondence. In addition, under 21 CFR 314.82(b)(2)(vii), we request that you include a status summary of each commitment in your annual report to this NDA. The status summary should include the number of patients entered in each study, expected completion and submission dates, and any changes in plans since the last annual report. For administrative purposes, all submissions, including labeling supplements, relating to these Phase 4 commitments must be clearly designated "Phase 4 Commitments."

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 FR 66632). We note that you have not fulfilled the requirements of 21 CFR 314.55 (or 601.27). We are deferring submission of your pediatric studies until March 1, 2001. However, in the interim, please submit your pediatric drug development plans within 120 days from the date of this letter unless you believe a waiver is appropriate. Within approximately 120 days of receipt of your pediatric drug development plan, we will review your plan and notify you of its adequacy.

If you believe that this drug qualifies for a waiver of the pediatric study requirement, you should submit a request for a waiver with supporting information and documentation in accordance with the provisions of 21 CFR 314.55 within 60 days from the date of this letter. We will notify you within 120 days of receipt of your response whether a waiver is granted. If a waiver is not granted, we will ask you to submit your pediatric drug development plans within 120 days from the date of denial of the waiver.

Pediatric studies conducted under the terms of section 505A of the Federal Food, Drug, and Cosmetic Act may result in additional marketing exclusivity for certain products (pediatric exclusivity). You should refer to the *Guidance for Industry on Qualifying for Pediatric Exclusivity* (available on our web site at www.fda.gov/cder/pediatric) for details. If you wish to qualify for pediatric exclusivity you should submit a "Proposed Pediatric Study Request" (PPSR) in addition to your plans for pediatric drug development described above. We recommend that you submit a Proposed Pediatric Study Request within 120 days from the date of this letter. If you are unable to meet this time frame but are interested in pediatric exclusivity, please notify the division in writing. FDA generally will not accept studies submitted to an NDA before issuance of a Written Request as responsive to a Written Request. Sponsors should obtain a Written Request before submitting pediatric studies to an NDA. If you do not submit a PPSR or indicate that you are interested in pediatric exclusivity, we will review your pediatric drug development plan and notify you of its adequacy. Please note that satisfaction of the requirements in 21 CFR 314.55 alone may not qualify you for pediatric exclusivity. FDA does not necessarily ask a sponsor to complete the same scope of studies to qualify for pediatric exclusivity as it does to fulfill the requirements of the pediatric rule.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Kim Colangelo, Regulatory Project Manager, at (301) 827-4260.

Sincerely,



Susan Allen, M.D., M.P.H.
Acting Director
Division of Reproductive and Urologic Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

cc:

Archival NDA 21-015
HFD-580/Div. Files
HFD-580/K.Colangelo/T.Rumble/S.Allen/M.Mann
HFD-580/M.Hirsch/D.Shames/M.Rhee/D.Lin/A.Jordan
HFD-580/A.Parekh/D.Chatterjee
HF-2/MedWatch (with labeling)
HFD-002/ORM (with labeling)
HFD-103/ADRA (with labeling)
HFD-102/Post-Marketing PM
HFD-104/Peds/V.Kao (with labeling)
HFD-40/DDMAC (with labeling)
HFI-20/Press Office (with labeling)
HFD-400/OPDRA (with labeling)
HFD-613/OGD (with labeling)
HFD-095/DDMS-IMT (with labeling)
HFD-006/C.Moody
HFD-820/DNDC Division Director
DISTRICT OFFICE

Drafted by: kmc/February 18, 2000

Initialed by: Mann, Shames, Hirsch, Rhee, Lin, Chatterjee, 02.25.00; Jordan, Parekh, Rumble, Allen, 02.28.00

final: Colangelo, 02.28.00

filename: c:\data\mydocs\nda\21-015\n000ap.doc

APPROVAL (AP) (with Phase 4 Commitments)

**APPEARS THIS WAY
ON ORIGINAL**